Hartington Pharmaceutical, SLU

Hartington Pharmaceutical, S.L.U. is a Spain-based small and medium-sized enterprise operating through several dedicated research and development divisions, each addressing a distinct and clearly defined innovation domain. The company focuses on translating science-driven concepts into regulated, scalable, and market-ready solutions.

Natural Products and Regulated Healthcare Division
This division is dedicated to the development, manufacturing coordination, and international licensing of natural product–based healthcare solutions. It includes established and late-stage products such as Nasodren®, Lazolex®, Lazonail®, and Lazo Be-Feet®. Activities cover applied research and development, regulatory strategy, clinical and post-market support, industrial scale-up, and global commercialization through licensing and distribution partnerships.

Digital Innovation and Neurotechnology Division
Hartington develops and licenses advanced technological solutions in the field of brain–computer interfaces [BCI], with a focus on the CortexControl platform. This division works on non-invasive and hybrid neurotechnological systems, signal acquisition and processing, artificial intelligence–assisted interpretation, and real-time control applications. Target use cases include neurorehabilitation, assistive technologies, and advanced human–machine interaction. The division contributes system integration expertise, industrial validation, and exploitation planning within collaborative research projects.

Advanced Prosthetic Engineering Division
This division focuses on the research and engineering of next-generation prosthetic solutions. Activities include the development of intelligent prosthetic systems, sensor integration, control architectures, and interface technologies, with particular attention to interoperability with neurotechnological platforms. The objective is to enable functional, adaptive, and clinically relevant prosthetic solutions suitable for translational research and applied innovation programmes.

Gene Therapy and Orphan Diseases Research Division
Hartington conducts early-stage exploratory research in gene therapy approaches targeting orphan and rare diseases. This division focuses on concept development, biological validation strategies, and translational pathways aimed at generating proof-of-concept assets suitable for further preclinical development and collaborative research under Horizon Europe and similar frameworks.

Across all divisions, Hartington actively participates in international research consortia, contributing industrial perspective, regulatory awareness, and structured pathways toward real-world deployment. The company prioritizes collaborations that combine scientific excellence with clear exploitation strategies and measurable societal or industrial impact.